IPM Take
MOGAD has a treatment problem partly because it has a prediction problem.
Some patients experience a single inflammatory attack and never relapse. Others enter a recurrent course in which each new episode puts vision, spinal-cord function or neurological recovery at risk. Treating everyone aggressively exposes some people to unnecessary long-term immunotherapy; waiting for another attack exposes others to preventable damage.
A newly published international study suggests antibodies against the MOGα3 isoform may help separate those groups. The finding is promising precisely because the decision it could inform is so consequential. It is also far too early to turn one biomarker into a treatment rule.
Executive Summary
Researchers evaluated antibodies against multiple MOG isoforms using international multicentre serum cohorts to determine whether particular antibody profiles could predict relapse in MOG antibody-associated disease.
The work began with 748 consecutive serum samples from patients evaluated for CNS demyelinating disease in Korea. Researchers then assessed relapse associations in a MOGAD derivation cohort and tested the findings in independent Korean and UK validation groups.
Presence of MOGα3 antibodies was associated with a higher relapse risk, with a reported hazard ratio of 4.3 in the derivation cohort. The association was also observed in an independent Korean validation cohort and in a subgroup of the UK validation cohort. The investigators classify the study as providing Class II evidence for diagnostic performance of the tested assays.
The findings require additional replication and assay standardisation before MOGα3 testing could be used routinely to decide who should receive preventive immunotherapy.
Why it matters
- MOGAD is particularly difficult because the first attack does not reliably reveal the future disease course. Clinicians have to balance the risks of recurrent neurological injury against the risks and burden of long-term immunotherapy.
- A credible relapse biomarker could make that decision more personalised. It could identify patients for whom earlier preventive treatment deserves stronger consideration while sparing some monophasic patients unnecessary long-term therapy.
- That possibility has become even more relevant as MOGAD-specific treatments move closer to regulatory approval. Better treatment without better risk stratification can still lead to overtreatment, undertreatment or payer criteria that are too crude.
Precision medicine is most useful when uncertainty carries consequences.
In MOGAD, the difficult question often comes after the patient has recovered from the first attack. Should long-term preventive treatment begin immediately, with the burden and risks of chronic immunotherapy, or should clinicians wait to see whether another attack occurs?
Waiting can be clinically reasonable in a monophasic disease. It can also mean allowing the second attack to reveal the diagnosis of relapsing disease by causing new damage.
That is why the MOGα3 finding is worth attention. The study did not simply discover an association in one dataset. Investigators used a derivation-and-validation approach across cohorts in Korea and the United Kingdom, strengthening the argument that the signal deserves further development.
But biomarker enthusiasm needs boundaries. The study does not prove that treating every MOGα3-positive patient immediately improves long-term outcomes. Assays will require standardisation, and predictive performance must be tested prospectively in clinically diverse populations.
The potential, however, is substantial. MOGAD treatment is entering a more mature era. The next version of that care pathway should not ask only what drug prevents relapse? It should also ask whose relapse risk is high enough to justify treating before the next attack occurs?
